ArticleBlood advances2019
Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children.
Open access · goldAbstract readClinical Trial, Phase I
In one paragraph
Article in Blood advances, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 1 pooled it
5.2field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.
- The role of chemokines and interleukins in acute lymphoblastic leukemia: a systematic review.Journal of applied biomedicine · 2024Pooled it
- Safety, pharmacokinetics, and pharmacodynamics of MK-6194, an IL-2 mutein designed to selectively activate regulatory T cells: single ascending dose and multiple ascending dose trial data.ImmunoHorizons · 2025Trial
- A randomized double-blind placebo-controlled trial of low-dose interleukin-2 in relapsing-remitting multiple sclerosis.Journal of neurology · 2023Trial
- Inefficiency of two-stage designs in phase II oncology clinical trials with high proportion of inevaluable patients.Contemporary clinical trials · 2022Trial
- Regulatory T cells: From Foxp3 to tolerance-inducing therapies.The Journal of investigative dermatology · 2026Review
- Review
- Review
- Regulatory T cell therapy for Graft-versus-Host Disease.Bone marrow transplantation · 2025Review
- Cytokine Couture: Designer IL2 Molecules for the Treatment of Disease.ImmunoTargets and therapy · 2025Review
- Directed disruption of IL2 aggregation and receptor binding sites produces designer biologics with enhanced specificity and improved production capacity.Computational and structural biotechnology journal · 2025Article
- Graft-Versus-Host Disease Mouse Models: A Clinical-Translational Perspective.Methods in molecular biology (Clifton, N.J.) · 2025Review
- Innovations in Childhood Interstitial and Diffuse Lung Disease.Clinics in chest medicine · 2024Review
- Tracing immune cells around biomaterials with spatial anchors during large-scale wound regeneration.Nature communications · 2023Article
- Chronic GvHD NIH Consensus Project Biology Task Force: evolving path to personalized treatment of chronic GvHD.Blood advances · 2023Article
- Children's Oncology Group's 2023 blueprint for research: Cellular therapy and stem cell transplantation.Pediatric blood & cancer · 2023Article
- Real-world experience with low-dose IL-2 for children and young adults with refractory chronic graft-versus-host disease.Blood advances · 2023Article
- More evidence for low-dose IL-2 for chronic GVHD in children.Blood advances · 2023Article
- Immunopathogenic mechanisms and modulatory approaches to graft-versus-host disease prevention in acute myeloid leukaemia.Best practice & research. Clinical haematology · 2023Review
- IL-2-based approaches to Treg enhancement.Clinical and experimental immunology · 2023Review
- Novel Pharmacological Treatment Options of Steroid-Refractory Graft-versus-Host Disease.Advances in hematology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 4 institutions in 1 country.
Jennifer S WhangboDivision of Hematology-Oncology, Boston Children's Hospital, Boston, MA.
Haesook T KimDepartment of Data Sciences, Dana-Farber Cancer Institute, Boston, MA.
Nikola MirkovicDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston MA.
Lauren LeonardDivision of Hematology-Oncology, Boston Children's Hospital, Boston, MA.
Samuel PoryandaDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston MA.
Sophie SilversteinDivision of Hematology-Oncology, Boston Children's Hospital, Boston, MA.
Soomin KimDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston MA.
Carol G ReynoldsDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston MA.
Sharmila C RaiDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston MA.
Kelly VerrillDivision of Hematology-Oncology, Boston Children's Hospital, Boston, MA.
Michelle A LeeDivision of Hematology-Oncology, Boston Children's Hospital, Boston, MA.
Steven MargossianDivision of Hematology-Oncology, Boston Children's Hospital, Boston, MA.
Christine DuncanDivision of Hematology-Oncology, Boston Children's Hospital, Boston, MA.
Leslie LehmannDivision of Hematology-Oncology, Boston Children's Hospital, Boston, MA.
Jennifer HuangHarvard Medical School, Boston, MA.
Sarah NikiforowHarvard Medical School, Boston, MA.
Edwin P AlyeaHarvard Medical School, Boston, MA.
Philippe ArmandHarvard Medical School, Boston, MA.
Corey S CutlerHarvard Medical School, Boston, MA.
Vincent T HoHarvard Medical School, Boston, MA.
Bruce R BlazarMasonic Cancer Center and Division of Blood and Marrow Transplantation, Department of Pediatrics, University of Minnesota, Minneapolis, MN.
Joseph H AntinHarvard Medical School, Boston, MA.
Robert J SoifferHarvard Medical School, Boston, MA.
Jerome RitzHarvard Medical School, Boston, MA.ORCID 0000-0001-5526-4669
John KorethHarvard Medical School, Boston, MA.
Harvard University · USBoston Children's Hospital · USDana-Farber Cancer Institute · USUniversity of Minnesota · US
Funding
Trial Design and Biostatistical Support CoreP01CA065493 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Mark J Osborn · 1995 to 2026
$48.2MTransgenic/KnockoutP01AI056299 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI SHARPE, ARLENE H. · 2003 to 2023
$42.5MProject 3: Humoral Targets and B Cell Biology in Chronic Graft-vs.-Host DiseaseP01CA142106 · NCI · DANA-FARBER CANCER INST · PI CUTLER, COREY S · 2009 to 2019
$17.5MSingle Cell and ImmunogenomicsP01CA229092 · NCI · DANA-FARBER CANCER INST · PI SOIFFER, ROBERT JON · 2019 to 2023
$13.8MEnhancing Treg Therapeutic Efficacy in GVHDR01HL118979 · NHLBI · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, HIPPEN, KELI L · 2014 to 2025
$6.7MManipulation of Immune Responsiveness after Hematopoietic Cell TransplantationR01CA183559 · NCI · DANA-FARBER CANCER INST · PI RITZ, JEROME, SOIFFER, ROBERT JON · 2013 to 2017
$3.7MReconstitution of Regulatory T Cells After Stem Cell TransplantationR01CA183560 · NCI · DANA-FARBER CANCER INST · PI RITZ, JEROME, SOIFFER, ROBERT JON · 2013 to 2017
$2.5MNCI NIH HHS P01 CA065493NCI NIH HHS P01 CA142106NCI NIH HHS P01 CA229092NCI NIH HHS R01 CA183559NCI NIH HHS R01 CA183560NHLBI NIH HHS R01 HL118979NIAID NIH HHS P01 AI056299
Abstract
Low-dose interleukin-2 (IL-2) therapy for chronic graft-versus-host disease (cGVHD) generates a rapid rise in plasma IL-2 levels and CD4
Indexed as
AdultCell ProliferationChildChronic DiseaseFemaleGraft vs Host DiseaseHumansImmunotherapyInterleukin-2Killer Cells, NaturalLung DiseasesMaleMaximum Tolerated DoseSkin DiseasesT-Lymphocytes, RegulatoryInterleukin-2
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.